PepGen Inc. (PEPG)
NASDAQ (NGS) NASDAQ (NGS) Primary 
PEPG Investors Can Participate In The PepGen Inc Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds PepGen Investors of the Ongoing Investigation into Potential Violations of Securities Laws – PEPG
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
Investors who lost money on PepGen Inc. should contact Levi & Korsinsky about an ongoing investigation - PEPG
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
Levi & Korsinsky Announces an Investigation on Behalf of PepGen Inc. (PEPG) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG.
PEPG STOCK ALERT: Levi & Korsinsky Notifies PepGen Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
PEPG Investors Have Opportunity To Join PepGen Inc Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Did PepGen Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PEPG
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG.
Did PepGen Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- PEPG
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG.
ATTENTION PEPG SHAREHOLDERS: Investors who Lost Money on PepGen Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
